Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
Cancer Res. 2024 Jan 16;84(2):291-304. doi: 10.1158/0008-5472.CAN-23-0184.
Approximately one-third of endocrine-treated women with estrogen receptor alpha-positive (ER+) breast cancers are at risk of recurrence due to intrinsic or acquired resistance. Thus, it is vital to understand the mechanisms underlying endocrine therapy resistance in ER+ breast cancer to improve patient treatment. Mitochondrial fatty acid β-oxidation (FAO) has been shown to be a major metabolic pathway in triple-negative breast cancer (TNBC) that can activate Src signaling. Here, we found metabolic reprogramming that increases FAO in ER+ breast cancer as a mechanism of resistance to endocrine therapy. A metabolically relevant, integrated gene signature was derived from transcriptomic, metabolomic, and lipidomic analyses in TNBC cells following inhibition of the FAO rate-limiting enzyme carnitine palmitoyl transferase 1 (CPT1), and this TNBC-derived signature was significantly associated with endocrine resistance in patients with ER+ breast cancer. Molecular, genetic, and metabolomic experiments identified activation of AMPK-FAO-oxidative phosphorylation (OXPHOS) signaling in endocrine-resistant ER+ breast cancer. CPT1 knockdown or treatment with FAO inhibitors in vitro and in vivo significantly enhanced the response of ER+ breast cancer cells to endocrine therapy. Consistent with the previous findings in TNBC, endocrine therapy-induced FAO activated the Src pathway in ER+ breast cancer. Src inhibitors suppressed the growth of endocrine-resistant tumors, and the efficacy could be further enhanced by metabolic priming with CPT1 inhibition. Collectively, this study developed and applied a TNBC-derived signature to reveal that metabolic reprogramming to FAO activates the Src pathway to drive endocrine resistance in ER+ breast cancer.
Increased fatty acid oxidation induced by endocrine therapy activates Src signaling to promote endocrine resistance in breast cancer, which can be overcome using clinically approved therapies targeting FAO and Src.
约三分之一的雌激素受体阳性(ER+)乳腺癌内分泌治疗女性由于内在或获得性耐药而有复发风险。因此,了解 ER+乳腺癌内分泌治疗耐药的机制对于改善患者治疗至关重要。已经表明,线粒体脂肪酸β氧化(FAO)是三阴性乳腺癌(TNBC)中的主要代谢途径,可激活Src 信号。在这里,我们发现 ER+乳腺癌中增加 FAO 的代谢重编程是对内分泌治疗产生耐药性的一种机制。在 TNBC 细胞中抑制 FAO 限速酶肉碱棕榈酰转移酶 1(CPT1)后,从转录组学、代谢组学和脂质组学分析中得出了一个与代谢相关的综合基因特征,该 TNBC 衍生特征与 ER+乳腺癌患者的内分泌耐药显著相关。分子、遗传和代谢组学实验鉴定出在内分泌耐药的 ER+乳腺癌中 AMPK-FAO-氧化磷酸化(OXPHOS)信号的激活。体外和体内的 CPT1 敲低或 FAO 抑制剂治疗显著增强了 ER+乳腺癌细胞对内分泌治疗的反应。与之前在 TNBC 中的发现一致,内分泌治疗诱导的 FAO 激活了 ER+乳腺癌中的 Src 通路。Src 抑制剂抑制了内分泌耐药肿瘤的生长,并且通过 CPT1 抑制进行代谢启动可以进一步增强疗效。总之,这项研究开发并应用了一个源自 TNBC 的特征来揭示,代谢重编程为 FAO 激活 Src 通路,从而推动 ER+乳腺癌的内分泌耐药。
内分泌治疗诱导的脂肪酸氧化增加激活 Src 信号,促进乳腺癌的内分泌耐药,使用针对 FAO 和 Src 的临床批准疗法可以克服这种耐药性。